Related Experiment Videos
Heparin and platelets
1Department of Pathology, McMaster University Medical Centre, Hamilton, Ontario, Canada.
Hematology/Oncology Clinics of North America
|February 1, 1990
Summary
Heparin-induced thrombocytopenia (HIT) is a serious immune reaction linked to blood clots. Minimizing heparin exposure and using porcine heparin can reduce HIT risk.
Area of Science:
- Immunology
- Pharmacology
- Hematology
Background:
- Heparin-induced thrombocytopenia (HIT) is a critical immune-mediated adverse drug reaction.
- It is characterized by a significant risk of arterial and venous thromboembolism.
- The true incidence of HIT may be underestimated due to sub-thrombocytopenic platelet falls.
Purpose of the Study:
- To review the immune mechanisms underlying HIT.
- To discuss strategies for mitigating the risk of HIT and associated thrombosis.
- To highlight the need for safer anticoagulant alternatives.
Main Methods:
- Review of existing literature on heparin-induced thrombocytopenia.
- Analysis of immune mechanisms involving heparin-antibody complexes.
- Evaluation of clinical data on heparin-induced thrombosis incidence and risk factors.
Main Results:
- The majority of HIT cases, with or without thrombosis, are immune-driven.
- Heparin-antibody immune complexes activate platelets via Fc receptors.
- Incidence rates vary: 1% for porcine mucosal heparin, 5% for bovine lung heparin.
Conclusions:
- Minimizing heparin exposure duration and utilizing porcine heparin can reduce HIT risk.
- Monitoring platelet counts and prompt anticoagulation changes are crucial for recognized HIT.
- Development of non-thrombocytopenic heparinoids is desired.